BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Tamoxifen
,
rs4950928
,
ERBB2
,
nitric oxide metabolic process
,
Lung cancer
,
Lymphocyte
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
CP 115 953
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for CP 115 953
Explore Curated Studies Results
Literature
Most Relevant Literature
Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded…
Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA…
A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomer…
CP-115,953 stimulates cytokine production by lymphocytes.
Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in dru…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Pat…
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chro…
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway I…
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ